CoChat

Genetic testing for retinal dystrophies and dysfunctions: benefits, dilemmas and solutions

Koenekoop, Robert K, Lopez, Irma, Den Hollander, Anneke I, Allikmets, Rando, Cremers, Frans PM · 2007 · Clinical & Experimental Ophthalmology
Cited by 125

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Human retinal dystrophies have unparalleled genetic and clinical diversity and are currently linked to more than 185 genetic loci. Genotyping is a crucial exercise, as human gene‐specific clinical trials to study photoreceptor rescue are on their way. Testing confirms the diagnosis at the molecular level and allows for a more precise prognosis of the possible future clinical evolution. As treatments are gene‐specific and the ‘window of opportunity’ is time‐sensitive; accurate, rapid and cost‐effective genetic testing will play an ever‐increasing crucial role. The gold standard is sequencing but is fraught with excessive costs, time, manpower issues and finding non‐pathogenic variants. Therefore, no centre offers testing of all currently 132 known genes. Several new micro‐array technologies have emerged recently, that offer rapid, cost‐effective and accurate genotyping. The new disease chips from Asper Ophthalmics (for Stargardt dystrophy, Leber congenital amaurosis [LCA], Usher syndromes and retinitis pigmentosa) offer an excellent first pass opportunity. All known mutations are placed on the chip and in 4 h a patient's DNA is screened. Identification rates (identifying at least one disease‐associated mutation) are currently ∼70% (Stargardt), ∼60–70% (LCA) and ∼45% (Usher syndrome subtype 1). This may be combined with genotype–phenotype correlations that suggest the causal gene from the clinical appearance (e.g. preserved para‐arteriolar retinal pigment epithelium suggests the involvement of the CRB1 gene in LCA). As ∼50% of the retinal dystrophy genes still await discovery, these technologies will improve dramatically as additional novel mutations are added. Genetic testing will then become standard practice to complement the ophthalmic evaluation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1442-9071.2007.01534.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 125

Metadata

Authors
Koenekoop, R. K., Lopez, I., Den Hollander, A. I., Allikmets, R., & Cremers, F. P.
Venue
Clinical & Experimental Ophthalmology
Publisher
Wiley
Published
2007-07
Volume
35
Issue
5
Pages
473-485
ISSN
  • 1442-6404 (ISSN-L)
  • 1442-9071
OpenAlex
W2150467649
Cited by
125
References
3
FWCI
4.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Genetic testing for retinal dystrophies and dysfunctions: benefits, dilemmas and solutions. https://app.cochat.ai/papers/10.1111/j.1442-9071.2007.01534.x
The paper
Koenekoop, R. K., Lopez, I., Den Hollander, A. I., Allikmets, R., & Cremers, F. P. (2007). Genetic testing for retinal dystrophies and dysfunctions: benefits, dilemmas and solutions. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/j.1442-9071.2007.01534.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.